Patrys has developed two humanised forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody, and which have been further optimised for efficacy and manufacturability.
Patrys, and its’ commercial partners, are also using the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells.
Patrys is in the process of scaling up the manufacture of clinical grade PAT-DX1 with the first human clinical trial expected to commence in mid 2023.